You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 23, 2024

Claims for Patent: 10,144,749

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,144,749

Title:	Gold complexes of alkylated phosphines
Abstract:	Gold(I) complex with mixed ligands as an anticancer agent. The gold(I) ion is coordinated to a dithiocarbamate ligand and a phosphorus-containing ligand (e.g. phosphines). Also described are a pharmaceutical composition incorporating the gold(I) complex, a methods of synthesizing the gold(I) complex, and a method for treating cancer.
Inventor(s):	Al-Jaroudi; Said S. (Dhahran, SA), Alhoshani; Ali (Riyadh, SA), Altaf; Muhammad (Dhahran, SA), Isab; Anvarhusein Abdulkadir (Dhahran, SA)
Assignee:	King Fahd University of Petroleum and Minerals (Dhahran, SA) King Saud University (Riyadh, SA)
Application Number:	15/993,163
Patent Claims:	1. A gold(I) complex represented by formula (I): ##STR00006## a salt thereof, a solvate thereof, or a combination thereof; wherein R.sub.1 and R.sub.2 are alkyl groups independently selected from the group consisting of methyl, ethyl, and isopropyl; R.sub.3, R.sub.4, and R.sub.5 are independently selected from the group consisting of an optionally substituted C.sub.1-C.sub.3 alkyl, an optionally substituted arylalkyl, an optionally substituted aryl, an optionally substituted vinyl, an optionally substituted alkoxy, and an optionally substituted aryloxy; and with the proviso that R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5 are not each an ethyl. 2. The gold(I) complex of claim 1, wherein R.sub.1 and R.sub.2 are the same unsubstituted alkyl group, and R.sub.3, R.sub.4, and R.sub.5 are the same optionally substituted C.sub.1-C.sub.3 alkyl group. 3. The gold(I) complex of claim 2, wherein R.sub.1 and R.sub.2 are ethyls, and R.sub.3, R.sub.4, and R.sub.5 are methyls. 4. A composition comprising: the gold(I) complex of claim 1; and a pharmaceutically acceptable carrier or excipient. 5. The composition of claim 4, which comprises 0.01-50 .mu.M of the gold(I) complex relative to the total composition. 6. The composition of claim 4, further comprising: at least one chemotherapeutic agent selected from the group consisting of aflibercept, asparaginase, bleomycin, busulfan, carmustine, chlorambucil, cladribine, cyclophosphamide, cytarabine, dacarbazine, daunorubicin, doxorubicin, etoposide, fludarabine, gemcitabine, hydroxyurea, idarubicin, ifosfamide, irinotecan, lomustine, mechlorethamine, melphalan, mercaptopurine, methotrexate, mitomycin, mitoxantrone, pentostatin, procarbazine, topotecan, vinblastine, vincristine, retinoic acid, oxaliplatin, carboplatin, 5-fluorouracil, teniposide, amasacrine, docetaxel, paclitaxel, vinorelbine, bortezomib, clofarabine, capecitabine, actinomycin D, epirubicin, vindesine, methotrexate, 6-thioguanine, tipifarnib, imatinib, erlotinib, sorafenib, sunitinib, dasatinib, nilotinib, lapatinib, gefitinib, temsirolimus, everolimus, rapamycin, bosutinib, pzopanib, axitinib, neratinib, vatalanib, pazopanib, midostaurin, enzastaurin, trastuzumab, cetuximab, panitumumab, rituximab, bevacizumab, mapatumumab, conatumumab, and lexatumumab. 7. The gold(I) complex of claim 1, wherein R.sub.3, R.sub.4, and R.sub.5 are an C.sub.1-C.sub.2 alkyl group. 8. The gold(I) complex of claim 1, wherein R.sub.1 and R.sub.2 are the same alkyl group selected from the group consisting of a methyl group and an ethyl group, and R.sub.3, R.sub.4, and R.sub.5 are the same alkyl group selected from the group consisting of a methyl group and an ethyl group. 9. The gold(I) complex of claim 1, wherein R.sub.1 and R.sub.2 are methyls and R.sub.3, R.sub.4, and R.sub.5 are ethyls.

Details for Patent 10,144,749

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978	⤷ Try a Trial	2036-04-22
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997	⤷ Try a Trial	2036-04-22
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998	⤷ Try a Trial	2036-04-22
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017	⤷ Try a Trial	2036-04-22
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004	⤷ Try a Trial	2036-04-22
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.